8-K: Immunome Reports Q2 2026 Results, Varegacestat NDA Accepted

Immunome announced its second quarter 2026 financial results, highlighting the FDA's acceptance of the New Drug Application for varegacestat with a PDUFA target action date of April 28, 2027, and providing updates on its clinical pipeline.

Summary

• Immunome reported its financial results for the second quarter ended June 30, 2026, and provided a business update.
• The U.S. FDA accepted the New Drug Application (NDA) for varegacestat for the treatment of adults with desmoid tumors, with a PDUFA target action date set for April 28, 2027.
• Detailed Phase 3 RINGSIDE trial data for varegacestat was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showing statistically significant improvements in the primary and all key secondary endpoints.
• The first patient was dosed in June 2026 for the Phase 1 trial of IM-1617, a solid tumor antibody-drug conjugate (ADC).
• The first patient was dosed in July 2026 for the Phase 1 trial of IM-3050, a fibroblast activation protein (FAP)-targeted radioligand therapy.
• As of June 30, 2026, the company had $520.0 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028.
• Research and development expenses for the quarter were $59.9 million, and general and administrative expenses were $18.3 million.
• The company reported a net loss of $73.1 million for the quarter.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to significant clinical trial progress and regulatory milestones, balanced by ongoing operational losses.

Positives

• FDA acceptance of the NDA for varegacestat with a PDUFA target action date of April 28, 2027, is a significant regulatory milestone.
• Phase 3 RINGSIDE trial data for varegacestat demonstrated a statistically significant 84% reduction in the risk of disease progression or death versus placebo (hazard ratio = 0.16, p<0.0001).
• The RINGSIDE trial met all key secondary endpoints, including a confirmed objective response rate of 56% versus 9% with placebo (p<0.0001).
• Varegacestat demonstrated statistically significant improvement in worst pain intensity at week 12, with a clinically significant difference observed as early as week 4.
• Three additional clinical-stage programs (IM-1021, IM-1617, IM-3050) are advancing with patients being dosed.
• The company expects its current cash position of $520.0 million to fund operations into 2028.
• Plans to submit a Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026.

Negatives

• The company reported a net loss of $73.1 million for the second quarter of 2026.
• Research and development expenses increased to $59.9 million for the quarter, compared to $40.5 million in the prior year period.
• General and administrative expenses increased to $18.3 million for the quarter, compared to $10.0 million in the prior year period.
• Net loss per share was $0.65 for the quarter, compared to $0.50 in the prior year period.

Risks

• The risk that regulatory approvals for Immunome's programs and product candidates are not obtained, are delayed, or are subject to unanticipated conditions.
• The risk that preclinical data may not be predictive of clinical data or that early clinical data may not be predictive of later clinical data, regulatory approval, or commercial viability.
• The risk of reliance on third-party vendors.
• The risk that Immunome's programs and product candidates fail to achieve their intended endpoints.
• Uncertainties related to Immunome's capital requirements and expected cash runway.
• The risk that Immunome will not be able to realize the benefits of its strategic transactions.
• The risk that Immunome's ability to grow and advance its pipeline and successfully execute on its business plan may be impacted.

Future Outlook

Immunome expects its current cash position to fund operations into 2028. The company anticipates submitting a Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026. Investigational New Drug (IND) applications for IM-1340 and IM-3050 are expected in midand late 2026, respectively. Additional undisclosed ADCs are in discovery and lead optimization for INDs in 2027 and beyond. Management believes the current momentum positions the company well for a milestone-rich second half of 2026.

Management Comments

• "We continue to execute against our strategy of building a diversified targeted oncology company with multiple opportunities to bring needed therapies to patients," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome.
• "For varegacestat, the presentation of detailed Phase 3 RINGSIDE data at ASCO and subsequent FDA acceptance of our NDA with a PDUFA target action date of April 28, 2027 represent important steps toward a potential approval and launch."
• "We are also continuing to advance our broader pipeline, with three additional clinical-stage programs now enrolling patients."
• "We believe this momentum positions us well for a milestone-rich second half of 2026."

Industry Context

StockSavvy.ai notes that Immunome's progress aligns with the broader biotechnology sector's focus on targeted therapies and oncology. The advancement of multiple clinical-stage programs, including ADCs and radioligand therapies, reflects industry trends towards precision medicine. The FDA's acceptance of the varegacestat NDA is a significant event in the competitive landscape for desmoid tumor treatments.

Comparison to Industry Standards

• The Phase 3 RINGSIDE trial for varegacestat demonstrated a statistically significant 84% reduction in the risk of disease progression or death, which is a strong outcome compared to placebo-controlled trials in similar oncology indications.
• The objective response rate of 56% for varegacestat in the RINGSIDE trial significantly outperforms the 9% observed with placebo, indicating a substantial therapeutic effect.
• The company's cash runway extending into 2028 is a positive indicator, providing stability for continued R&D investment, which is crucial in the capital-intensive biopharmaceutical industry.
• The progression of multiple drug candidates (IM-1617, IM-3050) into Phase 1 trials demonstrates a robust pipeline development strategy, comparable to other emerging biotechs focused on novel cancer therapeutics.

Stakeholder Impact

• Shareholders: Positive impact from regulatory progress on varegacestat and pipeline advancement, balanced by ongoing net losses.
• Patients: Potential for new treatment options for desmoid tumors (varegacestat) and other solid tumors through pipeline development.
• Employees: Continued investment in R&D and pipeline progression may lead to growth and opportunities within the company.

Next Steps

• Submit Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026.
• Present initial lymphoma data for IM-1021 in 2026.
• Submit Investigational New Drug (IND) applications for IM-1340 and IM-1335 in midand late 2026, respectively.
• Continue advancing Phase 1 trials for IM-1617 and IM-3050.
• Continue discovery and lead optimization for additional undisclosed ADCs to support INDs in 2027 and beyond.

Key Dates

Recommendation

The company has achieved significant regulatory and clinical milestones with varegacestat, and its pipeline is advancing. However, the substantial net loss and ongoing R&D expenses necessitate a cautious approach. A 'hold' recommendation reflects the positive developments balanced against the inherent risks and financial performance typical of a clinical-stage biotech firm.

Keywords

Varegacestat, Desmoid Tumors, Oncology, Antibody-Drug Conjugate, Radioligand Therapy, Clinical Trials, NDA, FDA